Novel Approaches to Immuno-Inflammatory Disorders: Small Molecules vs. Biologics
The treatment landscape for immuno-inflammatory disorders has been dominated by biological therapies for the past two decades. However, emerging small molecule approaches offer compelling advantages including oral bioavailability, improved patient compliance, and potentially reduced manufacturing costs.
Recent advances in drug discovery technologies, particularly AI-enhanced screening platforms, have enabled the identification of novel small molecule modulators of cytokine pathways previously thought to be undruggable with traditional approaches.
Clinical Advantages
Small molecule therapeutics offer several key advantages over biologics, including simplified storage and administration, reduced immunogenicity risk, and the potential for combination therapies. These factors are driving renewed interest in small molecule drug discovery for immune disorders.
Related Articles
Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
Strategic partnership combines Chemspace's ultra-large chemical datasets and Enamine's REAL design principles with Orogen's AI-enabled DEL technology to advance next-generation drug discovery.
Orogen Therapeutics Announces Expansion of Scientific Advisory Board with Drug Discovery and Development Experts
Industry leaders Humphrey Gardner and Christopher Winter, PhD join Orogen's expanded SAB as the Company advances its AI-enabled DNA-encoded library platform.
"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."
Mark Pykett
CEO, Orogen Therapeutics